Guo-Liang Yu, Apollomics CEO
A $105M SPAC deal? Really? A biotech with deep China roots is making a now-rare flip onto Nasdaq
SPACs may be way down, but they aren’t completely out.
Apollomics, a biotech with deep roots in China and an HQ in California, is taking …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
